HongShan reports material October portfolio licensing and acquisition agreements

HongShan’s portfolio update describes Gilead’s proposed acquisition of HCXT-2001 rights from 瀚辰星泰, METiS cooperation with Lilly, and commercial agreements involving Dizal and Insilico. The asset acquisition remained proposed; no GP exit or investor return is inferred.